To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE) | MicrobiomeTrials← Back to trialsNCT07116473
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-11Est. Completion: 2037-11
Enrollment target: 250 participants Other microbiome trials you might be interested in
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a heart condition caused by a protein called transthyretin (TTR) build…
Innsbruck, AustriaEst. completion Apr 15, 2028
Transthyretin Cardiac Amyloidosis
The goal of this clinical trial is to learn if trimetazidine can improve blood flow in the heart in adults with transthy…
São Paulo, BrazilEst. completion Aug 1, 2027
Recruiting
Amyloidogenic Transthyretin (ATTR) AmyloidosisCardiac Amyloidosis
The goal of this study is to learn whether PET-CT imaging using evuzamitide can help diagnose transthyretin cardiac amyl…
Boston, United StatesEst. completion Mar 15, 2028